Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

European Journal of Cancer

Volumn 50, Issue 11, 2014, Pages 1855-1863

  Paul, Tanusree ^a   Schumann, Christian ^a   Rüdiger, Stefan ^a   Boeck, Stefan ^b   Heinemann, Volker ^b   Kächele, Volker ^a   Steffens, Michael ^c   Scholl, Catharina ^c   Hichert, Vivien ^c   Seufferlein, Thomas ^a   Stingl, Julia Carolin ^c,d  

^a UNIVERSITY OF ULM   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

CXCL8 IL 8; EGFR; EGFRI; Erk 1 2; Keratinocytes; Skin toxicity

Indexed keywords

CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PANITUMUMAB; PROTEIN C JUN; RANTES;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ERUPTION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOREGULATION; INCUBATION TIME; KERATINOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT BOWEL SYNDROME; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SUPERNATANT; WESTERN BLOTTING;

CXCL8/IL-8; EGFR; EGFRI; ERK 1/2; KERATINOCYTES; SKIN TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-8; KERATINOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN DISEASES;

EID: 84902244593     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.026     Document Type: Article

References (40)

1. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
2. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
3. S. Parmar, C. Schumann, S. Rüdiger, S. Boeck, V. Heinemann, and V. Kächele et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity Pharmacogenomics J 13 2013 1 8
4. R. Peréz-Soler, and L. Saltz Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23 2005 5235 5246
5. T. Li, and R. Perez-Soler Skin toxicities associated with epidermal growth factor receptor inhibitors Target Oncol 4 2009 107 119
6. E. Molinari, J. De Quatrebarbes, T. André, and S. Aractingi Cetuximab-induced acne Dermatology 211 2005 330 333
7. B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P.J. Cagnoni Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 2007 3913 3921
8. J.R. Brahmer, J.W. Lee, A.M. Traynor, M.M. Hidalgo, J.M. Kolesar, and J.M. Siegfried et al. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503) Eur J Cancer 50 2014 302 308
9. M. Miodovnik, R. Koren, E. Ziv, and A. Ravid The inflammatory response of keratinocytes and its modulation by vitamin D: the role of MAPK signaling pathways J Cell Physiol 227 2012 2175 2183
10. C. Kari, T.O. Chan, and M.R. De Quadros Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage Cancer Res 63 2003 1 5
11. S. Pastore, F. Mascia, F. Mariotti, C. Dattilo, V. Mariani, and G. Girolomoni ERK1/2 regulates epidermal chemokine expression and skin inflammation J Immunol 174 2005 5047 5056
12. G. Pearson, F. Robinson, T. Beers Gibson, B.E. Xu, M. Karandikar, and K. Berman et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr Rev 22 2001 153 183
13. M.S. Iordanov, R.J. Choi, O.P. Ryabinina, T. Dinh, R.K. Bright, and B.E. Magun The UV (Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor Mol Cell Biol 22 2002 5380 5394
14. R. Gillitzer, and M. Goebeler Chemokines in cutaneous wound healing J Leukoc Biol 69 2001 513 521
15. M.W. Carr, S.J. Roth, E. Luther, S.S. Rose, and T.A. Springer Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant Proc Natl Acad Sci 91 1994 3652 3656
16. L.L. Xu, M.K. Warren, W.L. Rose, W. Gong, and J.M. Wang Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro J Leukoc Biol 60 1996 365 371
17. M.L. Giustizieri, F. Mascia, A. Frezzolini, O. De Pità, L.M. Chinni, and A. Giannetti et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines J Allergy Clin Immunol 107 2001 871 877
18. B.H. Kim, Y.S. Lee, and K.S. Kang The mechanism of retinol-induced irritation and its application to anti-irritant development Toxicol Lett 146 2003 65 73
19. A. Smeets, B. Brouwers, S. Hatse, A. Laenen, R. Paridaens, and G. Floris et al. Circulating CCL5 levels in patients with breast cancer: is there a correlation with lymph node metastasis? ISRN Immunol 2013 2013 1 5
20. M.E. Lacouture Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 6 2006 803 812
21. F. Mascia, V. Mariani, G. Girolomoni, and S. Pastore Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation Am J Pathol 163 2003 303 312
22. S. Segaert, and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 2005 1425 1433
23. B.M. Lichtenberger, P.A. Gerber, M. Holcmann, B.A. Buhren, N. Amberg, and V. Smolle et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation Sci Transl Med 5 2013 199ra111
24. Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). U.S. Department of Health and Human Services, National Cancer Institute (NCI); 2006. p. 0-71.
25. M. Jost, T.M. Huggett, C. Kari, L.H. Boise, and U. Rodeck Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway J Biol Chem 276 2001 6320 6326
26. K. Xie Interleukin-8 and human cancer biology Cytokine Growth Factor Rev 12 2001 375 391
27. Y.S. Lee, I. Choi, Y. Ning, N.Y. Kim, V. Khatchadourian, and D. Yang et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis Br J Cancer 106 2012 1833 1841
28. D.J. Brat, A.C. Bellail, and E.G. Van Meir The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro-oncol 7 2005 122 133
29. C. Wilson, T. Wilson, P.G. Johnston, D.B. Longley, and D.J.J. Waugh Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells Mol Cancer Ther 7 2008 2649 2661
30. A.R. Green, V.L. Green, M.C. White, and V. Speirs Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours Int J Cancer 72 1997 937 941
31. P. Rutkowski, J. Kaminska, M. Kowalska, W. Ruka, and J. Steffen Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis Int J Cancer 100 2002 463 471
32. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival J Clin Oncol 19 2001 577 583
33. F. Luppi, A.M. Longo, W.I. de Boer, K.F. Rabe, and P.S. Hiemstra Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation Lung Cancer 56 2007 25 33
34. D.A. Arenberg, S.L. Kunkel, P.J. Polverini, M. Glass, M.D. Burdick, and R.M. Strieter Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice J Clin Invest 97 1996 2792 2802
35. N. Bangsgaard, M. Houtkamp, D.H. Schuurhuis, P.W.H.I. Parren, O. Baadsgaard, and H.W.M. Niessen et al. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor PLoS One 7 2012 e39706
36. R.A. Fakieh, S. Taha, and M. Bakhiet The role of IL-18, CCL5 and their receptors as diagnostic markers in breast cancer GERF Bull Biosci 3 2012 1 8
37. N. Lapteva, and X.F. Huang CCL5 as an adjuvant for cancer immunotherapy Expert Opin Biol Ther 10 2010 725 733
38. L. Hefler, C. Tempfer, G. Heinze, K. Mayerhofer, G. Breitenecker, and S. Leodolter et al. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients Br J Cancer 81 1999 855 859
39. M.J. Craig, and R.D. Loberg CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases Cancer Metastasis Rev 25 2006 611 619
40. G. Soria, and A. Ben-Baruch The inflammatory chemokines CCL2 and CCL5 in breast cancer Cancer Lett 267 2008 271 285